HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2006.068494v1 62/12/1069    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mackay, L. S Articles by Fisher, A. J Search for Related Content PubMed PubMed Citation Articles by Mackay, L. S Articles by Fisher, A. J

Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation

Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle upon Tyne and Applied Immunobiology and Transplantation Research Group, University of Newcastle, Newcastle upon Tyne, UK

Correspondence to:
Dr Andrew J Fisher, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK; A.J.Fisher{at}newcastle.ac.uk

Background: Lung transplantation is the only treatment modality that provides a survival advantage in pulmonary fibrosis, but many patients deemed suitable will die awaiting lung transplantation. While donor organ shortage undoubtedly contributes to this, late referral to the transplant centre may also play a role. This study investigates factors influencing the chance of patients with pulmonary fibrosis reaching lung transplantation.

Methods: A single-centre retrospective review of patient demographic data, assessment investigations and subsequent clinical outcomes was performed for patients with pulmonary fibrosis assessed for lung transplantation over a 5-year period.

Results: Between March 1999 and March 2004, 129 patients with pulmonary fibrosis underwent formal transplant assessment. Sixty-nine were accepted and listed for lung transplantation. Of these, 17 were transplanted, 37 died while waiting, 4 were removed from the list and 11 were still waiting at the conclusion of the study. The median waiting time on the list for those transplanted was 103 days (range 6–904) compared with 125 days (range 2–547) for those who died while on the list (p = 0.65). There was no significant difference in age, spirometry, total lung capacity, gas transfer measures or 6 min walk distance between those who died waiting and those transplanted. However, time from onset of symptoms to transplant assessment was significantly shorter in those who died on the waiting list (median 29 months (range 2–120)) than in those transplanted (median 46 months (range 6–204), p = 0.037).

Conclusion: Patients with pulmonary fibrosis who died awaiting transplantation had similar disease severity at assessment as those who achieved transplantation. However, the interval between symptom onset and transplant referral was significantly shorter in those who died while on the waiting list, suggesting they had more rapidly progressive disease. The rate of disease progression appears to be a more sensitive indicator for transplantation referral than any single physiological measure of disease severity and should act as an important trigger for early transplant referral.

Abbreviations: IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; PaO₂, PaCO₂, arterial oxygen and carbon dioxide tensions; PASP, pulmonary artery systolic pressure; UIP, usual interstitial pneumonia

This article has been cited by other articles:

				W A Wuyts, M Thomeer, L J Dupont, and G M Verleden An algorithm for referral of patients with IPF for lung transplantation Thorax, March 1, 2008; 63(3): 292 - 292. [Full Text] [PDF]